Efficacy and Safety of Riociguat in Early Pulmonary Vascular Disease: A Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2a Trial.
文献摘要
Background Pulmonary arterial hypertension therapies have not been systematically studied in early disease stages, despite potential benefit. Research question Is riociguat safe, well tolerated, and potentially effective in early pulmonary vascular disease? Study design and methods This was a prospective, multicenter, double-blind phase 2a trial. Adults with early pulmonary vascular disease, defined as mean pulmonary arterial pressure ≥ 25 mm Hg with pulmonary vascular resistance (PVR) ≥ 2 to Results Of 261 prescreened patients, 35 eligible patients were randomized to treatment (97% female; mean age, 65.5 ± 6.9 years; 77.1% connective tissue disease-associated pulmonary arterial hypertension); 32 completed the trial. Reasons for ineligibility were documented. Riociguat significantly improved the primary end point of change in PVR (riociguat -0.73 ± 0.67 WU vs placebo -0.02 ± 0.67 WU; P = .043; 27% placebo-adjusted reduction). No significant differences were observed in secondary end points. Of the exploratory end points, only cardiac output showed a trend toward improvement under riociguat (0.35 ± 0.86 L/min vs placebo -0.19 ± 0.75 L/min; P = .084). Only mild to moderate adverse events were observed, and serious events were not considered treatment related. Interpretation Despite the limited number of participants, treatment with riociguat was safe and significantly improved the primary end point PVR over 24 weeks. Clinical trial registration ClinicalTrials.gov; No.: NCT05339087; URL: www. Clinicaltrials gov).